HomeCompareMDT vs CQP

MDT vs CQP: Dividend Comparison 2026

MDT yields 3.31% · CQP yields 4.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CQP wins by $11.4K in total portfolio value
10 years
MDT
MDT
● Live price
3.31%
Share price
$85.74
Annual div
$2.84
5Y div CAGR
29.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$54.3K
Annual income
$9,789.15
Full MDT calculator →
CQP
CQP
● Live price
4.92%
Share price
$67.12
Annual div
$3.30
5Y div CAGR
25.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$65.7K
Annual income
$12,645.22
Full CQP calculator →

Portfolio growth — MDT vs CQP

📍 CQP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMDTCQP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MDT + CQP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MDT pays
CQP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MDT
Annual income on $10K today (after 15% tax)
$281.55/yr
After 10yr DRIP, annual income (after tax)
$8,320.78/yr
CQP
Annual income on $10K today (after 15% tax)
$417.91/yr
After 10yr DRIP, annual income (after tax)
$10,748.44/yr
At 15% tax rate, CQP beats the other by $2,427.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MDT + CQP for your $10,000?

MDT: 50%CQP: 50%
100% CQP50/50100% MDT
Portfolio after 10yr
$60.0K
Annual income
$11,217.19/yr
Blended yield
18.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MDT right now

MDT
Analyst Ratings
1
Strong
26
Buy
22
Hold
Consensus: Buy
Price Target
$111.45
+30.0% upside vs current
Range: $100.00 — $120.00
Altman Z
2.9
Piotroski
7/9
CQP
Analyst Ratings
3
Buy
5
Hold
10
Sell
Consensus: Sell
Price Target
$47.50
-29.2% upside vs current
Range: $44.00 — $55.00
Altman Z
2.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MDT buys
0
CQP buys
0
No recent congressional trades found for MDT or CQP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMDTCQP
Forward yield3.31%4.92%
Annual dividend / share$2.84$3.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR29.3%25.3%
Portfolio after 10y$54.3K$65.7K
Annual income after 10y$9,789.15$12,645.22
Total dividends collected$29.9K$39.5K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuySell
Analyst price target$111.45$47.50

Year-by-year: MDT vs CQP ($10,000, DRIP)

YearMDT PortfolioMDT Income/yrCQP PortfolioCQP Income/yrGap
1← crossover$11,128$428.29$11,316$616.05$188.00CQP
2$12,483$575.94$12,925$816.35$442.00CQP
3$14,138$780.71$14,921$1,091.85$783.00CQP
4$16,196$1,068.46$17,442$1,476.10$1.2KCQP
5$18,809$1,479.09$20,683$2,020.55$1.9KCQP
6$22,201$2,075.70$24,937$2,805.86$2.7KCQP
7$26,716$2,960.69$30,644$3,961.48$3.9KCQP
8$32,891$4,305.30$38,490$5,700.69$5.6KCQP
9$41,599$6,405.16$49,569$8,384.84$8.0KCQP
10$54,300$9,789.15$65,684$12,645.22$11.4KCQP

MDT vs CQP: Complete Analysis 2026

MDTHealthcare

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Full MDT Calculator →

CQPStock

Cheniere Energy Partners, L.P., through its subsidiaries, owns and operates natural gas liquefaction and export facility at the Sabine Pass liquefied natural gas (LNG) terminal located in Cameron Parish, Louisiana. The company's regasification facilities include five LNG storage tanks with an aggregate capacity of approximately 17 billion cubic feet equivalent; two marine berths that accommodate vessels with capacity of up to 266,000 cubic meters; and vaporizers with regasification capacity of approximately 4 billion cubic feet per day. It also owns a 94-mile pipeline that interconnects the Sabine Pass LNG terminal with various interstate pipelines. Cheniere Energy Partners GP, LLC serves as the general partner of the company. The company was founded in 2003 and is headquartered in Houston, Texas.

Full CQP Calculator →
📬

Get this MDT vs CQP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MDT vs SCHDMDT vs JEPIMDT vs OMDT vs KOMDT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.